IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-33825-5.html
   My bibliography  Save this article

Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial

Author

Listed:
  • Olli P. O. Nevalainen

    (University of Helsinki
    Tampere University
    City of Tampere
    Pirkanmaa Hospital District)

  • Saana Horstia

    (University of Helsinki)

  • Sanna Laakkonen

    (University of Helsinki)

  • Jarno Rutanen

    (Tampere University
    Tampere University Hospital)

  • Jussi M. J. Mustonen

    (City of Helsinki)

  • Ilkka E. J. Kalliala

    (Helsinki University and University Hospital Helsinki
    Imperial College London)

  • Hanna Ansakorpi

    (University of Oulu)

  • Hanna-Riikka Kreivi

    (University of Helsinki and Helsinki University Hospital)

  • Pauliina Kuutti

    (University of Helsinki)

  • Juuso Paajanen

    (University of Helsinki and Helsinki University Hospital)

  • Seppo Parkkila

    (Tampere University and Fimlab Ltd., Tampere University Hospital)

  • Erja-Leena Paukkeri

    (Tampere University Hospital)

  • Markus Perola

    (Finnish Institute for Health and Welfare
    University of Helsinki)

  • Negar Pourjamal

    (University of Helsinki)

  • Andreas Renner

    (University of Helsinki and Helsinki University Hospital
    University of Helsinki)

  • Tuomas Rosberg

    (Kanta-Häme Central Hospital)

  • Taija Rutanen

    (Suomen Covid -yhdistys ry)

  • Joni Savolainen

    (Suomen Covid -yhdistys ry)

  • Jari K. Haukka

    (Tampere University
    University of Helsinki)

  • Gordon H. Guyatt

    (McMaster University
    McMaster University)

  • Kari A. O. Tikkinen

    (University of Helsinki and Helsinki University Hospital
    South Karelian Central Hospital)

Abstract

We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.

Suggested Citation

  • Olli P. O. Nevalainen & Saana Horstia & Sanna Laakkonen & Jarno Rutanen & Jussi M. J. Mustonen & Ilkka E. J. Kalliala & Hanna Ansakorpi & Hanna-Riikka Kreivi & Pauliina Kuutti & Juuso Paajanen & Seppo, 2022. "Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial," Nature Communications, Nature, vol. 13(1), pages 1-6, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33825-5
    DOI: 10.1038/s41467-022-33825-5
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-33825-5
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-33825-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33825-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.